The Silent Burden of De Novo Metastatic Prostate Cancer in the Middle East
  • View Times: 57
  • |
  • Release Date: 2025-03-05
  • prostate cancer
  • de novo metastatic
  • middle east
  • screening guidelines
  • epidemiology
  • healthcare access
  • low–middle income countries
  • cancer awareness
  • resource-stratified strategies
  • review
Video Introduction

This video is adapted from 10.3390/siuj6010004

Prostate cancer is an increasing global health challenge, with a particularly significant impact in the Middle East. In this region, rising incidence rates and higher mortality ratios highlight critical gaps in healthcare access and quality.

This video explores the current state of prostate cancer in the Middle East, focusing on low- to middle-income settings. Researchers examine trends in incidence and mortality, the prevalence of de novo metastatic cases, and the urgent need for region-specific screening guidelines.

Key findings reveal that the Middle East has a mortality-to-incidence ratio of 0.3–0.4, compared to just 0.1 in the United States, reflecting stark disparities in outcomes. Countries like Lebanon report incidence rates as high as 37.2 per 100,000, while de novo metastatic cases often exceed 20–30%, reaching up to 54% in some studies.

These alarming statistics underscore the importance of tailored screening and early detection strategies.

Full Transcript
Video Production Service